Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Aytu Biopharma (AYTU) Assets Average (2016 - 2026)

Aytu Biopharma has reported Assets Average over the past 15 years, most recently at $123.5 million for Q4 2025.

  • Quarterly Assets Average rose 6.43% to $123.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $123.5 million through Dec 2025, up 6.43% year-over-year, with the annual reading at $121.1 million for FY2025, 4.83% down from the prior year.
  • Assets Average was $123.5 million for Q4 2025 at Aytu Biopharma, down from $124.6 million in the prior quarter.
  • Over five years, Assets Average peaked at $246.7 million in Q3 2021 and troughed at $116.0 million in Q4 2024.
  • The 5-year median for Assets Average is $133.4 million (2023), against an average of $146.9 million.
  • Year-over-year, Assets Average soared 67.5% in 2021 and then tumbled 41.71% in 2022.
  • A 5-year view of Assets Average shows it stood at $225.8 million in 2021, then plummeted by 35.46% to $145.7 million in 2022, then fell by 9.37% to $132.1 million in 2023, then dropped by 12.14% to $116.0 million in 2024, then rose by 6.43% to $123.5 million in 2025.
  • Per Business Quant, the three most recent readings for AYTU's Assets Average are $123.5 million (Q4 2025), $124.6 million (Q3 2025), and $124.2 million (Q2 2025).